ASCO® 2025 Highlights: Presenter Vignette – Frank Sinicrope
Frank Sinicrope
MD
Mayo Clinic Rochester
LBA1
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.
This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen
